Tenax Therapeutics is trading 5.6% up at $1.71 after rebounding from the August 10, 2026 collapse triggered by the failed Phase 3 LEVEL trial.
- The study missed its primary and key secondary endpoints, sending shares down nearly 90%, according to Reuters.
- No new company-specific announcement was found on August 12, so the gain appears to be a volatile rebound rather than a fresh fundamental catalyst.